JPWO2020205521A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020205521A5 JPWO2020205521A5 JP2021557927A JP2021557927A JPWO2020205521A5 JP WO2020205521 A5 JPWO2020205521 A5 JP WO2020205521A5 JP 2021557927 A JP2021557927 A JP 2021557927A JP 2021557927 A JP2021557927 A JP 2021557927A JP WO2020205521 A5 JPWO2020205521 A5 JP WO2020205521A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- subject
- poziotinib
- mutations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962826843P | 2019-03-29 | 2019-03-29 | |
| US62/826,843 | 2019-03-29 | ||
| PCT/US2020/025228 WO2020205521A1 (en) | 2019-03-29 | 2020-03-27 | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022527788A JP2022527788A (ja) | 2022-06-06 |
| JPWO2020205521A5 true JPWO2020205521A5 (es) | 2023-04-04 |
Family
ID=72666976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557927A Pending JP2022527788A (ja) | 2019-03-29 | 2020-03-27 | Ｅｇｆｒまたはｈｅｒ２エクソン２０挿入を有するがん細胞に対する抗腫瘍活性を有する化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220143023A1 (es) |
| EP (1) | EP3946293A4 (es) |
| JP (1) | JP2022527788A (es) |
| KR (1) | KR20210149103A (es) |
| CN (1) | CN113939284A (es) |
| AU (1) | AU2020254499A1 (es) |
| BR (1) | BR112021019489A2 (es) |
| CA (1) | CA3131864A1 (es) |
| IL (1) | IL286742A (es) |
| MX (1) | MX2021011948A (es) |
| SG (1) | SG11202110669WA (es) |
| WO (1) | WO2020205521A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110129434A (zh) * | 2018-02-08 | 2019-08-16 | 埃提斯生物技术（上海）有限公司 | 胆汁中生物标志物在诊断恶性肿瘤中的应用 |
| CA3131654A1 (en) | 2019-02-26 | 2020-09-03 | Janssen Biotech, Inc. | Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies |
| WO2020205521A1 (en) * | 2019-03-29 | 2020-10-08 | Board Of Regents, The University Of Texas System | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions |
| WO2020214824A1 (en) * | 2019-04-17 | 2020-10-22 | Board Of Regents, The University Of Texas System | Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations |
| JOP20210304A1 (ar) | 2019-05-14 | 2023-01-30 | Janssen Biotech Inc | علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث |
| UY39593A (es) * | 2020-12-29 | 2022-07-29 | Spectrum Pharmaceuticals Inc | Tratamiento para tumores sólidos malignos |
| CN115192580A (zh) * | 2021-04-01 | 2022-10-18 | 上海医药集团股份有限公司 | 一种化合物在制备靶向ErbB2突变体的抑制药物中的应用 |
| WO2023015149A1 (en) * | 2021-08-02 | 2023-02-09 | Spectrum Pharmaceuticals, Inc. | Treatment of non-small cell lung cancer with poziotinib |
| KR20230063731A (ko) | 2021-11-02 | 2023-05-09 | 주식회사 엘지에너지솔루션 | 전해액의 분할 주입을 포함하는 이차전지의 제조방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102627044B1 (ko) * | 2015-10-19 | 2024-01-18 | 선샤인 레이크 파르마 컴퍼니 리미티드 | Egfr 저해제의 염, 이의 결정질 형태 및 용도 |
| CN110291104B (zh) * | 2016-11-17 | 2023-11-03 | 得克萨斯州大学系统董事会 | 具有针对携带egfr或her2外显子20突变之癌细胞的抗肿瘤活性的化合物 |
| EP3687542A1 (en) * | 2017-09-27 | 2020-08-05 | AI Therapeutics, Inc. | Therapeutic methods relating to hsp90 inhibitors |
| KR20200132902A (ko) * | 2018-03-13 | 2020-11-25 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | Egfr 활성화 돌연변이를 갖는 암의 치료 방법 |
| KR20200136417A (ko) * | 2018-03-27 | 2020-12-07 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | Her2 엑손 19 돌연변이를 보유하는 암 세포에 대해 항 종양 활성을 갖는 화합물 |
| WO2020205521A1 (en) * | 2019-03-29 | 2020-10-08 | Board Of Regents, The University Of Texas System | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions |
-
2020
- 2020-03-27 WO PCT/US2020/025228 patent/WO2020205521A1/en unknown
- 2020-03-27 BR BR112021019489A patent/BR112021019489A2/pt not_active Application Discontinuation
- 2020-03-27 CN CN202080038791.0A patent/CN113939284A/zh active Pending
- 2020-03-27 CA CA3131864A patent/CA3131864A1/en active Pending
- 2020-03-27 KR KR1020217035240A patent/KR20210149103A/ko unknown
- 2020-03-27 US US17/599,969 patent/US20220143023A1/en active Pending
- 2020-03-27 EP EP20783802.0A patent/EP3946293A4/en active Pending
- 2020-03-27 SG SG11202110669WA patent/SG11202110669WA/en unknown
- 2020-03-27 JP JP2021557927A patent/JP2022527788A/ja active Pending
- 2020-03-27 AU AU2020254499A patent/AU2020254499A1/en active Pending
- 2020-03-27 MX MX2021011948A patent/MX2021011948A/es unknown
-
2021
- 2021-09-27 IL IL286742A patent/IL286742A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020502059A5 (es) | ||
| Bleeker et al. | IDH1 mutations at residue p. R132 (IDH1R132) occur frequently in high‐grade gliomas but not in other solid tumors | |
| CN107419018B (zh) | 一种基于Blocker引物和ARMS引物检测基因突变的方法和试剂盒 | |
| US20240094208A1 (en) | MEK1 Mutation Conferring Resistance to RAF and MEK Inhibitors | |
| EP2505673B1 (en) | Polynucleotide primers for detecting PIK3CA mutations | |
| EP2348111A9 (en) | PROBES FOR DETECTING MUTATIONS OF kRas GENE, LIQUICHIP AND DETECTION METHODS THEREOF | |
| CN106148498B (zh) | Kras基因突变检测试剂盒及其应用 | |
| CN108949927B (zh) | 一种用于检测人类egfr基因突变的序列组合物及其试剂盒 | |
| EP2227558A1 (en) | Method for classifying cancer patients as responder or non-responder to immunotherapy | |
| JPWO2020205521A5 (es) | ||
| Hufnagl et al. | A modified Phenol-chloroform extraction method for isolating circulating cell free DNA of tumor patients | |
| Cavic et al. | Pharmacogenetics in cancer therapy-8 years of experience at the Institute for Oncology and Radiology of Serbia | |
| WO2011035538A1 (zh) | 用于定量检测egfr突变的试剂盒 | |
| RU2020134932A (ru) | Соединения с противоопухолевой активностью против раковых клеток, несущих мутации в экзоне 19her2 | |
| EP3150717A1 (en) | Pik3ca gene mutation detection kit | |
| CN113584161A (zh) | 一种芬太尼代谢标志物的检测试剂盒及其检测方法和应用 | |
| WO2011079524A1 (zh) | 用于定量检测k-ras突变的试剂盒 | |
| EP2540838A1 (en) | Kit for quantitative detection of braf mutation | |
| CN110964833B (zh) | 一种一管检测血浆游离dna中kras和braf基因突变的试剂盒 | |
| CN111560438B (zh) | 检测aml预后相关基因突变的引物组合物、试剂盒及其应用 | |
| JPWO2019191279A5 (es) | ||
| CN111635933A (zh) | 一种检测人kras基因2号外显子突变的pcr试剂盒 | |
| Pekarík et al. | Haplotype analysis of the fragile X syndrome gene FMR1 in the Czech Republic | |
| Sarma et al. | Promoter Hypermethylation of ATG16L2, TFAP2A, EBF2, Calcitonin, ABL1 Kinase Domain T315I Mutation Association with Imatinib Therapy Resistance and Median Survival in CML Patients of North-East India | |
| JPWO2020205632A5 (es) |